Miano_edit_Layout 1 23/09/2009 13:03 Page 19
Treatment of Benign Prostatic Hyperplasia in the Geriatric Patient
1. Fried LP, Tangen CM, Waltson J, et al.; J Gerontol A Biol Sci 22. Landi F, Russo A, Liperoti R, et al., Clin Pharmacol Ther, 42. Hill B, Belville W, Bruskewitz R, et al., J Urol,
Med Sci, 2001;56:M146–156. 2007;81:235–41. 2004;171:2336–40.
2. Council on Scientific Affairs, Arch Intern Med, 23. Lepor H, Williford WO, Barry MJ, et al., N Engl J Med, 43. Boyle P, Roberston C, Vaughan ED, Fitzpatrick JM, BJU Int,
1990;150:2459–72. 1996;335:533–9. 2004;94:83–8.
3. Jacobsen SJ, Girman CJ, Lieber MM, Urology, 2001;58 24. Debruyne FMJ, Jardin A, Colloi D, et al., Eur Urol, 44. Tubaro A, Hofner K, Villavicencio H, et al., Eur Urol Suppl,
(6 Suppl. 1):5–16. 1998;34:169–75. 2006;5(2):274, abstract 1006.
4. Meigs JB, Barry MJ, Giovannucci E, et al., J Urol, 25. Kirby RS, Roherborn C, Boyle P, et al., Urology, 45. Tan AH, Gilling PJ, Kennett KM, et al., J Urol,
1999;162:376–82. 2003;61:119–26. 2003;170:1270–74.
5. McConnell JD, Roehrborn CG, Baustita OM, et al., N Engl J 26. Boyle P, Gould AL, Roherborn CG, Urology, 46. Tooher R, Sutherland P, Costello A, et al., J Urol,
Med, 2003;349:2387–98. 1996;48:398–405. 2004;171:1773-81
6. McConnell JD, Bruskewitz R, Walsh P, et al., N Engl J Med, 27. Roherborn CG, Boyle P, Nickel JC, et al., Urology, 47. Tan AH, Gilling PJ, Curr Opin Urol, 2005;15:55–8.
1998;338:557–63. 2002;60:434–41. 48. Seki N, Mochida O, Kinukawa N, et al., J Urol,
7. AUA Practice Guidelines Committee, J Urol, 28. Harrison RH III, Boren JS, Robinson JR, J Urol, 2003;170:1847–50.
2003;170:530–47. 1956;75:95–110. 49. Kuntz RM, Lehrich K, Ahyai SA, Eur Urol,
8. Chatelain C, Denis L, Foo JKT, et al. In: Benign Prostatic 29. Ho HS, Yip SK, Lim KB, et al., Eur Urol, 2007;52(2):517–22. 2008;53(1):160–66.
Hyperplasia, 5th International Consultation on Benign Prostatic 30. Singh H, Desai MR, Shrivastav P, Vani K, J Endourol, 50. Ahyai SA, Lehrich K, Kuntz RM, Eur Urol, 2007;52:1456–64.
Hyperplasia (BPH), June 25–28, 2000, Paris, Plymouth: 2005;19(3):333–8. 51. Naspro R, Bachmann A, Gilling P, et al., Eur Urol,
Plymbridge Distributors Ltd, 2001;519–34. 31. de Sio M, Autorino R, Quarto G, et al., Urology, 2009;55:1345–57.
9. Steers WD, AUA News, 2007;12(4):15–16. 2006;67(1):69–72. 52. Malek RS, Kuntzman RS, Barret DM, J Urol,
10. Turnheim K, Exp Gerontol, 2003;38:843–53. 32. Starkman JS, Santucci RA, BJU Int, 2005;95(1):69–71. 2000;163:1730–33.
11. Shapiro E, Hartanto V, Lepor H, Prostate, 1992;21:297–307. 33. de la Rosette JJ, Francisca EA, Kortmann BB, BJU Int, 53. Malek RS, Kuntzman RS, Barret DM, J Urol,
12. Djavan B, Eur Urol Suppl, 2004;3:23–30. 2000;86:47–51. 2005;174:1344–8.
13. Lowe F, Narayan P, Djavan B, Eur Urol Suppl, 2002;1(1):108, 34. de Wildt MJ, Debruyne FM, de la Rosette JJ, Urology, 54. Bachmann A, Schurch L, Ruszat R, et al., Eur Urol,
abstract 42. 1996;48:416–23. 2005;48:965–71.
14. Buzelin JM, Fonteyne E, Kontturi M, et al., Br J Urol, 35. Thalmann GN, Mattei A, Treuthardt C, et al., J Urol, 55. Van Cleynenbreugel B, Srirangam SJ, Van Poppel H, Curr
1997;80:597–605. 2002;167:2496–2501. Opin Urol, 2009;19:33–7.
15. Lowe FC, Clin Ther, 1997;19:730–42. 36. d’Ancona FC, Francisca EA, Debruyne FM, de la Rosette 56. Ogiste JS, Cooper K, Kaplan SA, Curr Opin Urol,
16. Chapple C, Baert L, Thind P, et al., Eur Urol, JJ, J Endourol, 1997;11:285–9. 2003;13:51–7.
1997;32:462–70. 37. Vesely S, Knutson T, Dicuio M, et al., J Endourol, 57. Barber NJ, Roodhouse AJ, Rathenborg P, et al., BJU Int,
17. van Kerrebroeck P, Jardin A, van Cangh P, Laval KU, Eur 2005;19(6):730–33. 2005;96:578–80.
Urol, 2002;41:54–61. 38. Wagrell L, Schelin S, Nordling J, et al., Urology, 58. Corica AP, Larson BT, Sagaz A, et al., BJU Int,
18. Abdel-Aziz S, Mamalis N, Curr Opin Ophtalmol, 2004;64(4):698–702. 2004;93:346–8.
2009;20(1):37–41. 39. Mattiasson A, Schelin S, Magnusson B, et al., Urology, 59. Madersbacher S, Eur Urol, 2006;49:212–14.
19. Artibani W, Eur Urol Suppl, 2004;3:1–6. 2007;69(1):91–6. 60. Dineen MK, Shore ND, Lumerman JH, et al., Urology,
20. Kaplan SA, Roherborn GC, Rovner SE, et al., JAMA, 40. Schelin S, Eur Urol, 2001;39:400–404. 2008;71(5):873–7.
2006;296:2319–28. 41. Hoffman RM, Monga M, Elliot SP, et al., Cochrane Database
21. Ancelin ML, Artero S, Portet F, et al., BMJ, 2006;332:455–9. Syst Rev, 2007;(4):CD004135.
Performed by More Urologists
Worldwide
Have you seen the light?
Documented clinical outcomes equivalent to TURP with fewer complications…
Proven safe and effective in more than 375 clinical articles and abstracts…
532nm wavelength influencing procedural efficiency and patient outcomes.
It’s no wonder GreenLight is used by more urologists than
any other laser for the treatment of BPH.
Come see the light at www.GreenLightHPS.com
See the Instructions for Use and the Operator’s Manual for the complete directions,
contraindications, warnings and risks associated with the device.